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Angiotensin converting gene enzyme polymorphism: Potential silencer
motif and impact on progression in IgA nephropathy. Since the renin
angiotensin system (RAS) is established as an important factor in renal
disease progression, we determined whether RAS alleles that have been
linked to variability in outcome in several cardiovascular diseases also
affect progression of IgA nephropathy. These genetic variants include: (1)
angiotensin I converting enzyme deletion polymorphism in intron 16
(ACE l/D), reported to be associated with increased risk of myocardial
infarction as well as left ventricular hypertrophy; (2) a point mutation in
the angiotensinogen (Agt) gene resulting in a methionine to threonine
substitution at residue 235 (M235T), reported to be associated with
hypertension in Caucasians; and (3) an angiotensin receptor type I (ATR)
A to C transition at bp 1166 (A1166C) which shows synergy with the
deleterious effects of the ACE DD genotype in myocardial infarction. We
examined these polymorphisms by PCR amplification of genomic DNA
samples from 64 Caucasian patients in the USA (age 6 to 83 years) with
biopsy-proven IgA nephropathy whose renal status was followed for an
average of almost seven years. Patients who presented with and main-
tained normal serum creatinine (Cr, <1.5 mg/dl), had ACE genotype
frequencies of 11:35%, ID:61%, DD:4%. By contrast, in patients with
progression (initially normal Cr increased to a mean of 4.5 0.86 mg/dl),
ACE genotype frequencies were 11:22%, ID:44%, DD:33% (P = 0.057 by
Fishers's exact test, vs. non-progressors). The association of the DD
genotype with progression was even more striking when patients with
other risk factors (hypertension and/or heavy proteinuria) were excluded.
In this subgroup, the genotype frequencies in patients with stable creati-
nine versus those with deterioration in renal function was 53%, 47%, and
0% versus 0%, 40%, and 60%, respectively, for II, ID, and DD genotypes(P = 0.009 by Fisher's exact test, progressors vs. non-progressors).
Further, sequence analysis of the I gene polymorphism revealed a
potential 13 bp silencer motif. Neither the Agt 235T nor the ATR A 1166C
gene variants, however, was associated with deterioration of renal func-
tion. Taken together, these results indicate that, although polymorphism
in each of the three genes in the RAS system has been linked to
cardiovascular diseases, only the ACE l/D polymorphism is associated
with progressive deterioration in renal function in IgA nephropathy. Since
previous observations link ACE polymorphism with ACE activity, these
findings imply a widespread importance of ACE in modulating destructive
processes in different organs.
Understanding genotype-phenotype correlations has rapidly
expanded over the last decade. Single gene defects underlying
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many diseases, including cystic fibrosis, riephrogenic diabetes
insipidus, and Huntington's chorea have been discovered. In
addition, common diseases such as diabetes mellitus and systemic
hypertension, long held to be strongly related to family history and
now recognized as likely polygenic, are being defined at the gene
level. The prominent role of the renin-angiotensin system (RAS)
in cardiovascular regulation suggests that component gene abnor-
malities could modulate cardiovascular disease processes. Indeed,
polymorphisms in several genes within the RAS system have been
linked with cardiovascular disorders. A polymorphism of the
angiotensin I converting enzyme (ACE) gene has been described
consisting of the insertion or deletion (lID) of a 287 bp fragment
within intron 16. The homozygous deletion genotype is associated
with increased risk for myocardial infarction and also with left
ventricular hypertrophy [1, 2]. Moreover, the ACE (DD) poly-
morphism was shown to have synergy in its deleterious effects in
myocardial infarction with a polymorphic locus in another RAS
component gene, namely the angiotensin II type I receptor (ATR)
gene. The latter consists of an ATR adenosine to cytosine
transition at position 1166 (A1166C) in the 3' untranslated region
of the gene, which has also been associated with hypertension
independent of ACE [3, 4]. Finally, a point mutation of the
angiotensinogen gene (Agt), resulting in an amino acid substitu-
tion of threonine for methionine at position 235 (M235T), has
also been associated with essential hypertension [5, 6]. These
observations are of particular relevance in renal disease as the
RAS is now firmly established as an important factor in progres-
sion of renal damage and development of end-stage renal disease.
However, while the renin-angiotensin system is believed to be a
pivotal mechanism in this destructive process, and manipulating
the activity of this system is a major target for treatment, little
information exists regarding the potential importance of genetic
variation of the RAS as a determinant of progressive renal
damage.
This potential impact of RAS genetic variations is of particular
interest in diseases with a highly variable outcome, with incom-
plete understanding of risk factors for progression. IgA nephrop-
athy, the most common primary glomerulopathy in many areas of
the world, was believed to be a benign process when initially
described by Berger and Hinglais in 1968 [7]. However, IgA
nephropathy is now recognized to follow a variable course, with
progressive loss of renal function occurring in up to 40% of
patients [8—10]. Currently, risk factors recognized to predict poor
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outcome include hypertension, heavy proteinuria, and abnormal
renal function at the time of presentation. However, each of these
prognosticators reflects already existing and/or progressive renal
damage. The current study was designed to determine whether
genetic polymorphisms within the renin angiotensin system, which
exhibit association with cardiovascular diseases, are also associ-
ated with progressive renal deterioration independent of the
established clinical parameters which portend a poor outcome in
this setting.
Methods
Study subjects
Only Caucasian patients with biopsy-proven IgA nephropathy
were included in the study (N = 83). African Americans, who are
known to have different ACE I/D and ATR-C frequencies com-
pared with Caucasians (higher ACE D allele, lower ATR C allele
[11, 121) were excluded. Blood samples were obtained from
patients who were consecutively recruited from our clinics be-
tween 1987 to 1991 to participate in a study of immune regulation
in IgA nephropathy and tissue samples were obtained from newly
cut tissue blocks from patients who had undergone renal biopsy
for routine diagnosis. Only renal tissue preserved in paraffin block
form was utilized to avoid DNA contamination (see below).
Patients gave their written consent and the study was approved by
the appropriate hospital ethics committee. Diagnosis of IgA
nephropathy was based on established pathological criteria, in-
cluding mesangial expansion and the diagnostic presence of IgA
as the sole, predominant or co-dominant immunoglobulin [13].
Patients with other disease entities who had mesangial IgA
deposition were excluded as were patients with insufficient clinical
data (N = 19). Genotypes were thus evaluated in 64 patients (43
males and 21 females) who were aged 6 to 83 years at renal biopsy.
Follow up was obtained from the referring nephrologists. Since
treatment was not standardized, the potential impact of treatment
on patient outcome could not be evaluated. Hypertension was
defined as systolic or diastolic blood pressure above 95th percen-
tile for age [141. Heavy proteinuria was defined as the presence of
urinary protein excretion > 3.0 g/24 hr, or> 50 mg/kg/day, at any
time during the follow-up period. Values of 24 hour collections
for determination of proteinuria was available in 60 of the 64
patients.
Groups
First, all the individuals (N = 64) whose serum creatinine (Cr)
at last visit was < 1.5 mg/dl, were compared with those whose last
Cr was > 1.5 mg/dL. The average duration of follow-up in this
group was 6.8 0.6 years (range I month to 28.4 years, median
7.5 years). A subgroup of patients included only individuals whose
creatinine at presentation was < 1.5 mg/dl (N = 41). These
patients were subdivided into those who maintained a normal Cr
throughout the follow-up period (< 1.5 mg/dl) and compared with
those who developed progressive renal dysfunction. The average
duration of follow-up for this group was 7.4 0.8 years (range 1
to 15.3 years, median 8.3 years). A separate analysis was made in
patients with normal initial Cr who did not develop known
prognosticators of poor outcome in IgA nephropathy, namely,
moderate or severe hypertension (defined by The Joint National
Committee on Detection, Evaluation, and Treatment of High
Blood Pressure), or heavy proteinuria (> 3.0 g/24 hr) at any time
during the follow up period (N = 20). The average time of follow
up in this group was 6.9 1.0 years (range 1 to 13 years, median
8.5 years).
DNA isolation from blood and tissue
Nuclear DNA was isolated from peripheral leukocytes in whole
blood samples as previously described by us [151. The concentra-
tion of DNA in each sample was determined by optical density of
the purified DNA at 260 nM. Tissue sections (5 micron thickness)
were cut for DNA isolation from formalin-fixed, paraffin-embed-
ded renal biopsy specimens. Microtome surfaces were cleaned
with 0.2 M NaOH prior to sectioning of each biopsy to eliminate
DNA contamination. Tissue sections were deparaffinized with
xylene, then washed with 100% ethanol. Resulting tissue samples
were then incubated overnight at 55°C in 50 ml of a mixture of
0.05 M Tris, pH 8.3, 0.001 M EDTA, and 0.5% polyoxyethylene-
sorbitan monolaurate (Tween 20, Sigma Chemical Co., St. Louis,
MO, USA) and 0.4 mg Proteinase K (Sigma Chemical). After
digestion, samples were heated to 95°C for eight minutes to arrest
proteinase activity.
Determination of ACE genotypes
PCR amplification to detect ACE I/D polymorphism was
carried out in a 50 ml mixture of 1 mivi MgCl2, 50 ms KC1, 10 ifiM
Tris-HCI, pH 9.0, 0.1% Triton X-100, 200 mM deoxynucleotide
triphosphates, 0.48 m primers, and 1 U Taq polymerase (Pro-
mega, Madison, WI, USA), and 25 ng genomic DNA using the
previously published primers, 5 '-CTGGAGACCACTCCCATC-
CTflTCT-3' and 5 '-GATGTGGCCATCACATT'CGTCAGAT-
3'. Amplification with this primer pair produces --490 bp and
—190 bp products corresponding to the I and D alleles, respec-
tively [16—18]. Thermocycling, performed with a PTC-100 appa-
ratus in all PCR reactions (MJ Research, Watertown, MA, USA),
consisted of denaturation at 94°C for one minute, annealing at
63°C for one minute, and extension at 72°C for two minutes for 30
cycles, followed by a final extension at 72°C for five minutes. Ten
milliliters of PCR product were mixed with 2 ml of glycerol based
loading buffer, electrically size fractionated in 0.8% agarose gel
containing 1 mg/ml ethidium bromide, and visualized by ultravi-
olet transillumination (Fig. 1).
In view of preferential amplification of the D allele and
inefficiency in amplification of the I allele, mistyping of ID
heterozygotes as D homozygotes is possible [19]. To eliminate this
possibility, all samples found to be DD after amplification with the
above conventional primers were re-amplified with a recently
reported insertion-specific primer pair which recognizes the in-
serted sequence, 5 'TGGGACCACAGCGCCCGCCACTAC3'
and 5'TCGCCAGCCCTCCCATGCCCATAA3' [20]. Briefly, in-
sertion-specific amplification was performed in a 50 ml mixture of
1.5 ms MgCl2, 50 mM KC1, 10 mrvi Tris-HCI, 250 mrvi deoxynucle-
otide triphosphates, 0.4 mM primers, 3 U Taq polymerase, and 100
ng genomic DNA. Thermocycling consisted of 40 cycles of
denaturation at 94°C for one minute, and annealing/extension at
78°C for one minute, followed by final extension at 72°C for 10
minutes. Eleven percent of the samples assigned the DD genotype
by the initial screen were positive for the insertion by the
additional insertion-specific method and were thus classified as
ID. This rate of false positives is similar to the 10% recently found
by other investigators [181.
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Determination of angiotensinogen M235T genotype
Amplification of a 303 bp sequence encompassing the M235T
point mutation was performed in a 50 ml mixture of 0.83 mM
MgC12, 50 ms'i KCI, 10 m'i Tris-HCI, pH 9.0, 0.1% Triton X-100,
125 mt deoxynucleotide triphosphates, 1 unit Taq polymerase, I
mg genomic DNA, and 1.3 m of each of the primers 5'-
GATGCGCACAAGGTCCTGTC-3' and 5 '-CAGGGTGTCCA-
cACTGGGTCGC-3' [6]. Thermocycling consisted of initial de-
naturation at 94°C, followed by 30 cycles of denaturation at 94°C
for one minute, annealing at 66°C for one minute, and extension
at 72°C for one minute. A final extension period at 72°C for two
minutes followed. The most 3' guanosine residue in the latter
primer, not matching genomic DNA, creates a SfaNI recognition
site during amplification in the presence of the M235, but not
235T variant. Restriction endonuclease digestion of the resulting
PCR product with SfaNI (New England Biolabs, Beverly, MA,
USA) at 37°C was thus used for mutation detection. Digestion
products were separated in 10% polyacrylamide TBE Ready Gel
(Bio Rad, Hercules, CA, USA). For DNA visualization, com-
pleted gels were soaked in 0.8% ethidium bromide for one hour
and ultraviolet transilluminated.
Determination of angiotensin II receptor type I A1166C genotype
An 856 bp sequence encompassing the A1166C polymorphism
was amplified in a 50 ml mixture of 1.5 mivi MgCl2, 50 mi KC1, 10
mM Tris, 250 mM deoxynucleotide triphosphates, 3 U Taq poly-
merase, and 0.5 mg genomic DNA, and 0.4 m of each of the
following primers: 5 '-AATGC'FTGTAGCCAAAGTCACCT-3'
and 5'-GGCTITGCTTFGTCTTGTFG-3' [4]. ATR genotyping
was done in blood and not tissue samples due to difficulties in
reliably attaining the appropriate amplicon. Previous studies
describe difficulties in attaining PCR amplification from tissues of
DNA fragments which are in excess of 400 to 500 bps [211.
Thermocycling consisted of an initial denaturation of 94°C for two
minutes, 40 cycles of denaturation at 94°C for one minute,
annealing at 60°C for one minute, extension at 72°C for two
minutes, and a final extension time of 72°C for 10 minutes. The
1166 C allele contains an additional recognition site for the
restriction endonuclease DdE that is absent in the A 1166 allele.
Accordingly, PCR amplification products were digested at 37°C
with DdE I (Promega, Madison, WI, USA) and electrically
separated on a 2% agarose ethidium bromide gel.
Sequencing the ACE insert fragment
To further characterize the ACE inserted fragment, we deter-
mined the sequence of PCR products in II, ID and DD individ-
uals. The PCR products were initially cloned into a TA cloning
vector (In vitrogen, San Diego, CA, USA), and the nucleotide
sequence of the fragment was determined by the method of
Sanger, using a sequenase kit (Sequenase, U.S. Biochem. Corp.,
Cleveland, OH, USA).
Statistics
Clinical parameters are reported as mean standard error.
Statistical analyses were performed on the actual number of
genotypes/alleles and not on the relative percent levels. Subgroup
comparisons were made by Fisher's exact test. Possible interaction
among clinical parameters was assessed by logistic regression by a
TabJe 1. Genotype/allele frequencies for renin-angiotensin system
polymorphisms in IgA nephropathy
NI initial Cr
All patients NI initial Cr No HTN/Uprot
Non- Non- Non-
progress Progress progress Progress progress ProgressN 24 40 23 18 15 5
ACE I/D II 38 20 35 22° 53 0"
genotype
% ID 58 60 61 44 47 40
DD 4 20 4 33 0 60
Agt M235T MM 35 31 41 38 43 20
genotype
% MT 52 61 45 62 43 80
TT 13 8 14 0 14 0
ATRA1166CAA 35 61 32 63 14 80°
genotype
% AC 52 31 54 25 64 20
CC 13 8 14 12 21 0
Frequencies are given as percent. Abbreviations are: NI initial Cr,
patients with normal serum creatinine at presentation; NI initial Cr, No
HTN/Uprot, patients with normal serum creatinine at presentation and no
hypertension or heavy proteinuria at any time.
aP 0.05, genotype distribution in non-progressors vs. progressors
P < 0.005 genotype distribution in non-progressors vs. progressors
logistic model (Poisson). Contingency analysis was applied to
evaluate possible correlation amongst the genotypes.
Results
Polymorphisms of ACE gene
In this population of American Caucasians with IgA nephrop-
athy the ACE I/D, AtgM235T and ATR A1166C genotype
frequencies were 11:27, ID:59, and DD:14%; MM:32, MT:58, and
11:10%; AA:51, AC:39, and CC:10%, respectively (Table 1). The
genotype frequencies for angiotensinogen and ATR polymor-
phisms in this population with renal disease approximate those
reported for other Caucasian populations where only 10 to 20%
are homozygous for the mutated allele [4, 22]. The ACE DD
genotype frequency in the current cohort appears lower than the
25 to 30% reported for other Caucasian groups [2, 23]. However,
it is important to note that the current 14% may be closer to the
actual frequency of the DD genotype in the general population.
This is because the newest methodologies for determining ACE
genotype overcome the inherent inefficiency of I allele amplifica-
tion in heterozygotes, which likely overestimated the DD geno-
type frequency in previous analyses (Fig. 1). Indeed, insertion
specific PCR amplification reclassified 11% of DD genotypes as
having an insertion and thus as actually being ID. These findings
impact on the potential contribution of genetic polymorphism on
disease incidence. In this population, no skewing of genotype
frequencies toward the deleterious genotypes was detected,
thereby reiterating that occurrence of IgA nephropathy per se is
not influenced by polymorphism in these RAS genes.
To evaluate whether genetic polymorphism in RAS affects the
course of IgA nephropathy, we looked for genetic differences in
all 64 patients by comparing patients who, at last clinical evalua-
tion, had normal versus those with abnormal serum Cr (average,
1.1 0.1 mg/dl vs. 6.1 0.7 mg/dl, P < 0.05). In those patients
whose most recent Cr was, by definition, < 1.5 mg/dl, the ACE
genotype distribution was 38, 58, and 4% for II, ID, and DD,
Flanking Primer PCR
—490 bp —
—l9Obp —
335 bp
Insertion Specific PCR
1+ 1+ 1—
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Table 2. Patient characteristics at presentation and outcome
All patients (+) HTN (+)Heayproteinuria (+)HTN&heavy proteinuria
64 (38) 28 (21) 13 (7) 4 (1)
Parentheses indicate number that progressed.
respectively, and was not different than those with elevated Cr at
last visit, where the distribution was 20, 60, and 20% (P = NS,
non-progressors vs. progressors; Table 1). The allele frequency
was also not different between progressors and non-progressors
(I/D:67/33 vs. 50/50; P = NS, non-progressors vs. progressors).
Thus, evaluation at last visit revealed no differences in the ACE
genotype frequencies between patients who maintained normal
Cr and those with renal dysfunction.
However, this type of analysis encompasses not only genetic
predisposition but a variety of risk factors for progressive damage,
including renal dysfunction at the time of presentation. Clinical
parameters and outcome are given in Table 2. To determine
whether outcome could be predicted at the time of presentation,
we then analyzed only patients who presented with a normal
creatinine (N = 41). In patients who presented with and main-
tained normal creatinine (0.9 0.1 vs. 1.1 0.1 mg/dl, P = NS)
throughout follow-up, the ACE genotypes were 35, 61, and 4%.
This distribution was different in those who progressed (Cr
changed from 1.2 0.0 to 4.5 0.9 mg/dl, P < 0.05 where ACE
genotypes were 22, 44 and 33% for II, ID and DD genotypes; P =
0.057 by Fisher's exact test, non-progressors vs. progressors; Table
1, Fig. 2). A predominance of the D allele was also observed in
those with progression (I/D:65/35 vs. 44/56, P = 0.07 by Fisher's
exact test, non-progressors vs. progressors). To further distinguish
ACE D allele as a risk factor for progression, patients with known
prognosticators of poor outcome in IgA nephropathy were ex-
cluded and the genotype frequency reassessed in the remaining
population (N = 20). After exclusion of patients with hyperten-
sion or significant proteinuria, the association of the DD genotype
as well as the D allele with progressive decline in renal function
was even more striking. Thus, in patients with normal initial Cr
who at no time developed hypertension or heavy proteinuria the
ACE genotype frequencies were 53, 47, and 0% for II, ID and DD
(Cr of 0.89 0.06 mg/dl at presentation was 0.99 0.06 at last
visit, P = NS). By contrast, in patients with normal initial renal
function and no hypertension or heavy proteinuria whose renal
function declined, ACE genotype frequencies were 0, 40, and 60%
for II, ID, DD (P = 0.009 by Fisher's exact test, non-progressors
vs. progressors) (Fig. 2). Logistic model analysis revealed that the
predictive value of the ACE genotype is not significantly modified
by the addition of hypertension or proteinuria. Thus, patients
without hypertension who have the DD genotype are 7.5 times
more likely to develop progressive deterioration in renal function
than patients who do not have this genotype. In addition, this
analysis shows that genotype is an independent risk factor for
renal progression after adjusting for proteinuria. This analysis
revealed that the ACE genotype is an independent risk (incidence
relative risk, IRR = 7.499821, with a 95% confidence interval of
1.25318 to 44.88365, P = 0.027). Proteinuria is also an indepen-
dent variable after adjusting for the effect of ACE genotype (IRR
of 13.22625 and 95% confidence interval of 1.199311 to 145.8618,
P = 0.035). These additional analyses further strengthen our
Fig. 1. Ethidium bromide gel for PCR which used the outside flanking
primers for ACE I/D polymorphism (top). The longer band represents the
I allele (—490), while the smaller band represents the D allele (—190).
Ethidium bromide gel for PCR products using the insertion-specific PCR,
which yields a 335 base pair amplicon (bottom).
conclusion that ACE genotype impacts progression independently
of these previously identified parameters of proteinuria and
hypertension. Analysis of covariance revealed that ACE genotype
was a prognosticator independent of proteinuria and hyperten-
sion, although hypertension at presentation was associated with
increased creatinine throughout the course. No other clinical
prognosticators were found. In those with progressive deteriora-
tion of renal function, Cr increased from 1.2 0.1 mg/dl at
presentation to 1.8 0.3 at last follow-up (P < 0.05). Allele ratio
for the non-progressors was I/D:77/23. An inversion of the allele
frequency, with a D predominance was observed in those who
progressed I/D:20/80, (P = 0.002 by Fisher's exact test, non-
progressors vs. progressors). ACE genotype did not correlate with
specific polymorphisms of the other RAS genes examined.
Sequence of the 'inserted' segment in the ACE gene
To gain further insight into the potential significance of ACE
I/D alleles, we sequenced the polymorphic locus. Shown in Figure
3 is the I allele sequence. Presence or absence of the 287 bp
fragment was the sole difference between the I and the D
amplicons. The insertion matched the fragment described and
registered into GenBank/EMBL Data Bank by Soubrier [161. This
insert has homology with the family of human alu repeat se-
quences. Interestingly, examination revealed a 14 base pair repeat
sequence, 5'ATACAGTCAC]ITTT 3' (boxed in Fig. 3). This
sequence begins the insert, while the repeat abuts the end of the
inserted fragment, immediately outside the insert.
Polymorphisms of the angiotensinogen gene
When these same analyses were performed with respect to the
angiotensinogen M235T mutation, no genotype or allele fre-
quency differences were identified between groups. Thus, in
patients who, at the last follow-up visit, had normal Cr, genotype
frequencies were 35, 52, and 13% versus 31, 61 and 8% for MM,
MT, and TT, respectively in those with elevated Cr at last visit (P
= NS). For those who presented with and maintained stable renal
function throughout follow-up, genotype frequencies were 41, 45
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A
60
>0C
ci)
-40
ci)
>
20
B
60
>0C
ci)
C.ci) 40
a)a->0
20
Fig. 2. (A) Frequency of ACE genotypes in patients who maintained stable
renal Jinction (< 1.5 mg/dl, LI) and those who developed progressive renal
dysJhnction (). (B) Frequency of ACE genotypes in patients without
hypertension or heavy proteinuria who maintained stable renal function
(LI) and those who developed progressive renal dysfunction (•). Note, no
II patient in this group progressed, while no DD patient remained stable.
and 14% versus 38, 62, and 0% for MM, MT and TI, respectively,
in those who presented with normal Cr but experienced progres-
sive decline in renal function (NS). Genotype frequencies for
individuals with initially normal Cr without hypertension or heavy
proteinuria were 43, 43, and 14% versus 20, 80, and 0% for MM,
MT and TT, respectively, in those with initially normal Cr without
hypertension or heavy proteinuria who progressed (NS). Simi-
larly, no differences in the M or T allele frequencies were detected
between those who did poorly and those who maintained normal
function.
Polymorphisms of the angiotensin type 1 receptor gene
Analysis of genotype and allele frequencies were likewise
performed with respect to the angiotensin II type I receptor
A1166C polymorphism. Genotype frequencies for patients with
normal versus elevated last Cr were not different, 35, 52, and 13%
versus 61, 31, and 8%, respectively, for AA, AC and CC (NS).
Similarly, there were no differences in the genotype frequencies
between non-progressors and progressors who began with normal
Cr, 32, 54, and 13% versus 63, 25, and 12%, respectively, for AA,
AC and CC (NS). By contrast, analysis of individuals after
exclusion of hypertension or proteinuria revealed an excess of the
C allele in those with normal renal function who maintained
normal Cr. Thus, the genotype distribution for these patients was
14, 64, and 21%. In patients with initially normal Cr without
hypertension or heavy proteinuria who progressed, this frequency
was different, 80, 20, and 0%, respectively, for AA, AC and CC.
Discussion
The study shows that in a cohort of American Caucasians with
biopsy-proven IgA nephropathy, the distribution of genotypes for
the ACE lID polymorphism is remarkable for an increased
frequency of the DD genotype and the D allele in those patients
who ultimately experienced progressive decline in renal function
during follow-up compared to those whose function remained
stable over the same time. In contrast to the ACE lID findings, the
235T mutation of the angiotensinogen gene was not associated
with progression. Finally, the C allele of the A 1166C variant of
angiotensin type I receptor, which has previously been associated
with myocardial infarction, displaying synergy with the deleterious
effects of the ACE DD genotype, was rather significantly under-
represented in our patients who progressed. Thus, the C allele did
not appear to confer additional risk for poor outcome in patients
with IgA nephropathy.
That abnormal genes may cause disease is now firmly estab-
lished. Less fixed is the concept that genetic background may also
affect progression of a disease, although support for such a notion
has recently emerged. Thus, a variant of the interleukin-1 receptor
antagonist gene is associated with increased severity in several
immune mediated diseases such as systemic lupus erythematosus,
alopecia areata, and inflammatory bowel disease [24—26]. In the
current study, ACE I/D polymorphism was not predictive of
incidence of IgA nephropathy. Indeed, the frequency of the DD
genotype in this cohort was somewhat lower than that reported for
other Caucasian groups, likely reflecting more specific PCR
technique in the current study. However, the ACE gene DD
genotype was significantly more frequent in IgA patients with
progressive deterioration in renal function, supporting the idea
that genetic background impacts disease outcome. Notably, exclu-
sion of patients with known risk factors for progression, such as
hypertension and significant proteinuria, strengthened the associ-
ation of the DD genotype and progression of renal dysfunction in
IgA nephropathy. The association between DD genotype and
outcome in another setting, namely, cardiovascular disease, was
also strengthened by the exclusion of known risk factors.
Schunkert et al demonstrated that the association of the D allele
with left ventricular hypertrophy was stronger in normotensive
than hypertensive patients, reiterating the idea of ACE l/D
polymorphism as a predictor of outcome, independent of known
prognosticators of cardiac hypertrophy [2]. Similarly, the ACE DD
genotype was a particularly potent predictor of myocardial infarction
in middle aged men otherwise considered to be at low risk [11.
The impact of ACE lID polymorphism in IgA nephropathy has
been shown beyond the current population, Yoshida et al inves-
tigated the consequences of the ACE polymorphism in IgA
nephropathy patients in Japan, which has the highest frequency of
IgA nephropathy in the world 18]. As in the current study,
significantly higher frequency of DD was present in patients with
declining renal function. Moreover, excess D allele was also seen
II ID DD
ACE genotype
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in subanalysis of only normotensives who progressed, and was
more apparent when patients without hypertension or impaired
renal function at presentation were analyzed. Another recent
report of IgA patients from Great Britain also found significant
association of the DD genotype with progressive decline in renal
function in IgA nephropathy [27]. Taken together, these observa-
tions suggest that while environmental and other genetic factors
may contribute, similar ACE polymorphism distributions predict
progressive IgA nephropathy in genetically distinct and geograph-
ically remote populations. These data point to a significant
functional role for the deletion allele of the ACE polymorphism.
Although the DD genotype is associated with poor outcome in a
variety of settings, it is also possible that it is the corresponding
decrease of the beneficial effects of the I allele, rather than the
presence of the D allele, which impacts this finding. The de-
creased ACE levels seen in II genotype patients lends credence to
this supposition [28].
Scrutiny of the sequence of ACE intron 16 encompassing the
I/D segment revealed a repeated sequence, comprising 14 termi-
nal bases of one end of the 'insert' and flanking the opposite end,
comprising the next 14 bases which follow the insert in Figure 3.
The arrangement of these two repeats suggests a possible origin of
the D allele. During meiosis, one of these two repeats could align
with the complement of the other, thus producing a 'loop-out' of
the intervening 287 bp fragment. This observation suggests that
the nature of the mutational event may actually be deletion rather
than insertion. Interesting in this regard, is the positive correlation
of circulating ACE levels with increasing preponderance of the D
allele in normal Caucasians [28]. That is, those with the II
genotype have the lowest serum ACE levels, DD subjects have the
highest, and those with the ID genotype have intermediate levels,
suggesting that the D allele contributes to the activation of ACE.
This suggests that the 'insert' may contain a silencer motif, the
absence of which activates the ACE gene. Of note, remarkable
homology between a 13 base pair sequence of the ACE insertion
fragment and a negative regulatory element in the renin Ren-1
suggests possible broad implications of this sequence as a poten-
tial silencer motif in the regulation of RAS activity [29]. Further
mechanistic potential of the ACE polymorphism comes from the
observation of increased systemic pressor responsiveness to infu-
sion of angiotensin I in normotensive men with the DD genotype
when compared with II genotypes [30]. The plasma concentra-
tions of angiotensin II were also higher across the dose range of
angiotensin I infusion implying increased generation of angioten-
sin II in the DD individuals. Nonetheless, it is also possible that
the identified polymorphic locus, while affecting ACE levels, may
only be a marker for another gene variant which more directly
contributes to renal functional deterioration.
The RAS affects progression in many settings [31, 32]. Further
support for the role of RAS comes from observations of superiority
of ACEI over other antihypertensive therapy in lessening renal
damage and decreasing cardiac hypertrophy [33—35]. Of note, serum
ACE levels are elevated in microalbuminuric diabetic patients who
are likely to develop progressive renal loss [36, 37]. Further, interor-
gan variability in synthesis/availability of angiotensin II has been
shown in animals, with plasma versus kidney Ang Il/Ang I ratios, 0.3
versus - 2.0, indicating more ready conversion of available Ang I to
Ang II in the kidney [38]. It is possible therefore, that the ACE l/D
polymorphism may be particularly relevant at the tissue level, such
that individuals with the DD genotype may, via enhanced Ang II
activity, demonstrate even more striking renal Ang II predominance
than the other genotypes.
In summary, these data indicate that among the three genes of
the renin angiotensin system studied, only angiotensin converting
enzyme, but not angiotensinogen or angiotensin type 1 receptor
gene polymorphism was associated with progressive renal deteri-
oration in patients with IgA nephropathy. This association was not
predictive of the risk for acquiring IgA nephropathy, but instead
was linked to progressive decline in renal function in patients
presenting with normal creatinine. Notably, this association be-
came even more significant when other known prognosticators
were eliminated, suggesting that ACE polymorphism is an inde-
pendent marker of poor outcome in this setting. These findings
are consistent with the emerging role of angiotensin converting
enzyme in modulating the slow, progressive destruction observed
in many renal diseases. The exact mechanisms whereby this
genetic polymorphism impacts the progression remain to be
elucidated, although the implications of the described mutational
loop-out of the ACE I/D are intriguing.
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